{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:03:56Z","timestamp":1762459436395,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24592269","15K10480"],"award-info":[{"award-number":["24592269","15K10480"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Development Program of EA Pharma Co., Ltd. and Takeda Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00198-016-3848-4","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T06:34:53Z","timestamp":1480487693000},"page":"1279-1286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-5009","authenticated-orcid":false,"given":"T.","family":"Mawatari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"3848_CR1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00198-008-0661-8","volume":"19","author":"EM Lewiecki","year":"2008","unstructured":"Lewiecki EM, Watts NB (2008) Assessing response to osteoporosis therapy. Osteoporos Int 19:1363\u20131368","journal-title":"Osteoporos Int"},{"key":"3848_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1385\/JCD:6:4:307","volume":"6","author":"EM Lewiecki","year":"2003","unstructured":"Lewiecki EM (2003) Nonresponders to osteoporosis therapy. J Clin Densitom 6:307\u2013314","journal-title":"J Clin Densitom"},{"key":"3848_CR3","first-page":"1980","volume":"27","author":"A del Puente","year":"2000","unstructured":"del Puente A, Scognamiglio A, Itto E, Ferrara G, Oriente P (2000) Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis. J Rheumatol 27:1980\u20131983","journal-title":"J Rheumatol"},{"key":"3848_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1385\/JCD:6:4:315","volume":"6","author":"AM Sawka","year":"2003","unstructured":"Sawka AM, Adachi JD, Ioannidis G, Olszynski WP, Brown JP, Hanley DA, Murray T, Josse R, Sebaldt RJ, Petrie A, Tenenhouse A, Papaioannou A, Goldsmith CH (2003) What predicts early fracture or bone loss on bisphosphonate therapy? J Clin Densitom 6:315\u2013322","journal-title":"J Clin Densitom"},{"key":"3848_CR5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1359\/jbmr.060715","volume":"21","author":"S Adami","year":"2006","unstructured":"Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R, ICARO Study Group (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565\u20131570","journal-title":"J Bone Miner Res"},{"key":"3848_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/jbmr.2011","volume":"29","author":"D Prieto-Alhambra","year":"2014","unstructured":"Prieto-Alhambra D, Pag\u00e8s-Castell\u00e0 A, Wallace G, Javaid MK, Judge A, Nogu\u00e9s X, Arden NK, Cooper C, Diez-Perez A (2014) Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res 29:268\u2013274","journal-title":"J Bone Miner Res"},{"key":"3848_CR7","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","volume":"52","author":"S Boonen","year":"2004","unstructured":"Boonen S, McClung MR, Eastell R, Fuleiban GEH, Barton IP, Delmas P (2004) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. JAGS 52:1832\u20131839","journal-title":"JAGS"},{"key":"3848_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00198-008-0566-6","volume":"19","author":"S Adami","year":"2008","unstructured":"Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Silvestri S, Agnusdei D, Gentilella R, Nuti R (2008) Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int 19:1219\u20131223","journal-title":"Osteoporos Int"},{"key":"3848_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2474-3-6","volume":"3","author":"GA Heckman","year":"2002","unstructured":"Heckman GA, Papaioannou A, Sebaldt RJ, Ioannidis G, Petrie A, Goldsmith C, Adachi JD (2002) Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord 3:6","journal-title":"BMC Musculoskelet Disord"},{"key":"3848_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2012.03.026","volume":"51","author":"P Peris","year":"2012","unstructured":"Peris P, Mart\u00ednez-Ferrer A, Monegal A, Mart\u00ednez de Osaba MJ, Muxi A, Gua\u00f1abens N (2012) 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 51:54\u201358","journal-title":"Bone"},{"key":"3848_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/jbmr.1496","volume":"27","author":"A D\u00edez-P\u00e9rez","year":"2012","unstructured":"D\u00edez-P\u00e9rez A, Olmos JM, Nogu\u00e9s X, Sosa M, D\u00edaz-Curiel M, P\u00e9rez-Castrill\u00f3n JL, P\u00e9rez-Cano R, Mu\u00f1oz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, Gonz\u00e1lez-Mac\u00edas J (2012) Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27:817\u2013824","journal-title":"J Bone Miner Res"},{"key":"3848_CR12","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","volume":"23","author":"AS Carmel","year":"2012","unstructured":"Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is \u226533 ng\/ml. Osteoporos Int 23:2479\u20132487","journal-title":"Osteoporos Int"},{"key":"3848_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1210\/jc.2002-020400","volume":"88","author":"NB Watts","year":"2003","unstructured":"Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D (2003) Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542\u2013549","journal-title":"J Clin Endocrinol Metab"},{"key":"3848_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4158\/EP.8.3.202","volume":"8","author":"MS Gordon","year":"2002","unstructured":"Gordon MS, Gordon MB (2002) Response of bone mineral density to once-weekly administration of risedronate. Endocr Pract 8:202\u2013207","journal-title":"Endocr Pract"},{"key":"3848_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00198-008-0650-y","volume":"20","author":"S Adami","year":"2009","unstructured":"Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, Minisola S, Rossini M (2009) Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 20:239\u2013244","journal-title":"Osteoporos Int"},{"key":"3848_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"3848_CR17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, Vertebral Efficacy With Risedronate Therapy (VERT) Study Group (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"3848_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"JY Reginster","year":"2000","unstructured":"Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"3848_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s001980200135","volume":"13","author":"M Fukunaga","year":"2002","unstructured":"Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971\u2013979","journal-title":"Osteoporos Int"},{"key":"3848_CR20","first-page":"469","volume":"22","author":"K Kushida","year":"2004","unstructured":"Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group (2004) A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab 22:469\u2013478","journal-title":"J Bone Miner Metab"},{"key":"3848_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","volume":"32","author":"OH Sorensen","year":"2003","unstructured":"Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120\u2013126","journal-title":"Bone"},{"key":"3848_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00774-006-0706-z","volume":"24","author":"H Kishimoto","year":"2006","unstructured":"Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, Risedronate Phase III Research Group (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24:405\u2013413","journal-title":"J Bone Miner Metab"},{"key":"3848_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bone.2013.10.017","volume":"59","author":"H Hagino","year":"2014","unstructured":"Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T (2014) Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. Bone 59:44\u201352","journal-title":"Bone"},{"key":"3848_CR24","first-page":"261","volume":"21","author":"T Fujita","year":"1993","unstructured":"Fujita T, Orimo H, Inoue T, Kaneda K, Sakurai M, Morita R, Morii H, Yamamoto K, Sugioka Y, Inoue A, Hoshino Y, Kawaguchi H, Yamamoto I, Fukase M, Takaoka K (1993) Double-blind mulitcenter comparative study with alphacalcidol of etidronate disodium(EHDP) in involutional osteoporosis. Clin Eval 21:261\u2013302","journal-title":"Clin Eval"},{"key":"3848_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s007740050038","volume":"16","author":"H Orimo","year":"1998","unstructured":"Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139\u2013150","journal-title":"J Bone Miner Metab"},{"key":"3848_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s007740170001","volume":"19","author":"H Orimo","year":"2001","unstructured":"Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331\u2013337","journal-title":"J Bone Miner Metab"},{"key":"3848_CR27","unstructured":"Division of Metabolism and Endocrine Drug Products of the United States Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. US Food and Drug Administration"},{"key":"3848_CR28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"3848_CR29","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control 19:716\u2013723","journal-title":"IEEE Trans Autom Control"},{"key":"3848_CR30","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1001\/archinte.1997.00440430099012","volume":"157","author":"KE Ensrud","year":"1997","unstructured":"Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157:2617\u20132624","journal-title":"Arch Intern Med"},{"key":"3848_CR31","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1359\/JBMR.050104","volume":"20","author":"MC Hochberg","year":"2005","unstructured":"Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P, Ross PD, Baran D, FIT Research Group (2005) Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 20:971\u2013976","journal-title":"J Bone Miner Res"},{"key":"3848_CR32","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911\u20131930","journal-title":"J Clin Endocrinol Metab"},{"key":"3848_CR33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00223-009-9295-x","volume":"85","author":"M Ishijima","year":"2009","unstructured":"Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, Kurosawa H (2009) Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 85:398\u2013404","journal-title":"Calcif Tissue Int"},{"key":"3848_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00774-010-0200-5","volume":"29","author":"R Okazaki","year":"2011","unstructured":"Okazaki R, Sugimoto T, Kaji H, Fujii Y, Shiraki M, Inoue D, Endo I, Okano T, Hirota T, Kurahashi I, Matsumoto T (2011) Vitamin D insufficiency defined by serum 25-hydroxyvitamin D and parathyroid hormone before and after oral vitamin D3 load in Japanese subjects. J Bone Miner Metab 29:103\u2013110","journal-title":"J Bone Miner Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3848-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-016-3848-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3848-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T07:38:44Z","timestamp":1589441924000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-016-3848-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["3848"],"URL":"https:\/\/doi.org\/10.1007\/s00198-016-3848-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2016,11,30]]},"assertion":[{"value":"18 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Mawatari and Dr. Iwamoto have no conflict of interest to declare with respect to the work described herein.Mr. Muraoka discloses an employment relationship with EA Pharma Co., Ltd., Tokyo, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}